Production & Manufacturing

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through one of its subsidiaries, Jubilant HollisterStier LLC , has signed new contract with Eli Lilly for contract...

Recipharm, a leading contract development and manufacturing organisation (CDMO) and Enzymatica, a Swedish life science company specialising in products with a protective barrier, have signed a broadened contract for the manufacture of ColdZyme®. The agreement will involve an additional Recipharm...

Oxgene, a biotechnology company designing and developing scalable gene therapy technologies, has announced the launch of its scalable, plasmid-free manufacturing system for Adeno-associated virus (AAV). Oxgene’s new TESSA technology addresses industry-wide challenges associated with robust and reproducible AAV manufacture...

T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and...

Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca’s...

BioNTech SE announced the signing of a share purchase agreement with Novartis AG, Basel / Switzerland to acquire their GMP certified manufacturing facility in Marburg, Germany. The manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to...

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners...